Bayer Signs a License Agreement with Sensible Medical for its ReDS Technology in Europe

Shots:

• Bayer will utilize Sensible’s ReDS technology as a biomarker for monitoring lung congestion in a clinical study for patients with heart failure, making Bayer, Sensible’s largest customer in Europe
• The ReDS System is used as Point-of-Care device/marker of lung fluid, producing a Continuum of Care for patients with fluid management problems + HF/ recovering from coronary artery diseases
• The ReDS System is a wearable vest, quantifying the amount of lung fluid non-invasively and has received FDA’s 510 (k) & CE marking, currently being commercialized in the US

Click here to read full press release/ article | Ref: PRNewsWire | Image: Retail Design Blog